Alumis Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2836 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Nov 13th, 2025 2:15 pm
Alumis to Participate in Upcoming November Investor Conferences - Nov 4th, 2025 6:00 am
Positive Signs As Multiple Insiders Buy Alumis Stock - Sep 26th, 2025 4:22 am
Alumis to Participate in Upcoming September Investor Conferences - Aug 29th, 2025 5:00 am
Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Aug 16th, 2025 6:25 am
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 13th, 2025 2:05 pm
While institutions invested in Alumis Inc. (NASDAQ:ALMS) benefited from last week's 4.1% gain, individual investors stood to gain the most - Aug 10th, 2025 8:28 am
TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight - Aug 5th, 2025 3:31 pm
Alumis (ALMS) Merges with ACELYRIN - Jul 29th, 2025 8:23 am
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - Jul 24th, 2025 5:30 am
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary - Jul 14th, 2025 2:05 pm
Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy - May 30th, 2025 3:23 am
Alumis to Present at the Jefferies Global Healthcare Investor Conference - May 29th, 2025 2:15 pm
Analysts' Revenue Estimates For Alumis Inc. (NASDAQ:ALMS) Are Surging Higher - May 29th, 2025 12:53 pm
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis - May 29th, 2025 5:55 am
Alumis Completes Merger with ACELYRIN - May 21st, 2025 7:10 am
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - May 14th, 2025 2:05 pm
Alumis Stockholders Approve Merger with ACELYRIN - May 13th, 2025 11:00 am
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - May 13th, 2025 11:00 am
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - May 6th, 2025 2:30 pm